Literature DB >> 10713046

Pituitary tumor transforming gene (PTTG) transforming and transactivation activity.

Z Wang1, S Melmed.   

Abstract

Pituitary tumor transforming gene (PTTG) is a newly identified transforming gene, the functional mechanism of which is little understood. Computational analysis reveals a C terminus rich in Glu and Pro, a known characteristic of transcriptional activation domains. We report here that murine PTTG indeed possesses transactivation ability, which correlates highly with its transforming properties. Pro(139), Ser(159), Pro(157)-Pro(158)-Ser(159)-Pro(160) (PPXP motif), and Leu(120)-Asp(121)-Phe(122)-Asp(123)-Leu(124) were found to be important for transactivation. Mutation to Ala at a key Pro(139) residue not only disrupted the transactivation function but also resulted in the loss of transforming ability in NIH3T3 cells. A murine PTTG cDNA that encodes a variant C-terminal tail (Gly-Lys-Gly-Val-Arg-Ser-Asn-Gly-Cys-Lys-Asp-Leu-Val-Thr) was cloned. This novel PTTG is devoid of transactivation and transforming ability; deletion of its variant C-terminal tail restores both transactivation and transforming ability. These results show a high correlation between the transforming and transactivation functions of PTTG and also indicate that the novel PTTG variant may function as an endogenous competitor to wild-type PTTG.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713046     DOI: 10.1074/jbc.275.11.7459

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  11 in total

Review 1.  Update on prognostic factors in acromegaly: Is a risk score possible?

Authors:  E Fernandez-Rodriguez; F F Casanueva; I Bernabeu
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

Review 2.  Pathogenesis of prolactinomas.

Authors:  Anna Spada; Giovanna Mantovani; Andrea Lania
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

3.  Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.

Authors:  Anderson Alves da Rocha; Ricardo Rodrigues Giorgi; Sandra Valeria de Sa; Maria Lucia Correa-Giannella; Maria Angela Fortes; Ana Mercedes Cavaleiro; Marcio Carlos Machado; Valter Angelo Cescato; Marcello Delano Bronstein; Daniel Giannella-Neto
Journal:  Pituitary       Date:  2006       Impact factor: 4.107

4.  Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition.

Authors:  Y Tong; Y Tan; C Zhou; S Melmed
Journal:  Oncogene       Date:  2007-03-12       Impact factor: 9.867

Review 5.  Role of transcription factors in the pathogenesis of pituitary adenomas: a review.

Authors:  A Suhardja; K Kovacs; J Rutka
Journal:  J Neurooncol       Date:  2001-12       Impact factor: 4.130

Review 6.  Genesis of pituitary adenomas: state of the art.

Authors:  G Faglia; A Spada
Journal:  J Neurooncol       Date:  2001-09       Impact factor: 4.130

7.  Evidence for cooperative transforming activity of the human pituitary tumor transforming gene and human T-cell leukemia virus type 1 Tax.

Authors:  Sergey V Sheleg; Jean-Marie Peloponese; Ya-Hui Chi; Yan Li; Michael Eckhaus; Kuan-Teh Jeang
Journal:  J Virol       Date:  2007-05-16       Impact factor: 5.103

Review 8.  The pituitary tumor transforming gene in thyroid cancer.

Authors:  G D Lewy; N Sharma; R I Seed; V E Smith; K Boelaert; C J McCabe
Journal:  J Endocrinol Invest       Date:  2012-04-05       Impact factor: 4.256

9.  Tumorigenic potential of pituitary tumor transforming gene (PTTG) in vivo investigated using a transgenic mouse model, and effects of cross breeding with p53 (+/-) transgenic mice.

Authors:  Miranda Y Fong; Hanan Farghaly; Sham S Kakar
Journal:  BMC Cancer       Date:  2012-11-20       Impact factor: 4.430

10.  Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling.

Authors:  Y C Liao; J W Ruan; I Lua; M H Li; W L Chen; J R Y Wang; R H Kao; J H Chen
Journal:  Oncogene       Date:  2011-10-17       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.